ATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY
DURVALUMAB atlantic TRIAL supports clinical activity and ASTRAZENECA'S OVERALL Immuno-Oncology Strategy Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage NSCLC patients; full data to be presented at a scientific congress in 2016 Durvalumab monotherapy and combination trials on track in multiple cancers, including 1st-line therapy for NSCLC, head & neck and bladder cancers AstraZeneca today provided an update on preliminary findings from the ATLANTIC trial of durvalumab as 3rd-line or later stage therapy in patients with locally